C. Solas, A. Lafeuillade, and P. Halfon, Discrepancies between Protease Inhibitor Concentrations and Viral Load in Reservoirs and Sanctuary Sites in Human Immunodeficiency Virus-Infected Patients, Antimicrobial Agents and Chemotherapy, vol.47, issue.1, pp.238-281, 2003.
DOI : 10.1128/AAC.47.1.238-243.2003

S. Letendre, J. Marquie-beck, and E. Capparelli, Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System, Archives of Neurology, vol.65, issue.1, pp.65-70, 2008.
DOI : 10.1001/archneurol.2007.31

F. Collin, G. Chêne, and S. Retout, Indinavir Trough Concentration as a Determinant of Early Nephrolithiasis in HIV-1-Infected Adults, Therapeutic Drug Monitoring, vol.29, issue.2, pp.164-70, 2007.
DOI : 10.1097/ftd.0b013e318030839e

URL : https://hal.archives-ouvertes.fr/inserm-00168427

C. Flexner, HIV-protease inhibitors, N Engl J Med, vol.338, pp.1281-92, 1998.

V. Moltke, L. Greenblatt, D. Grassi, and J. , Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir, The Journal of Clinical Pharmacology, vol.11, issue.suppl 1, pp.106-117, 1998.
DOI : 10.1002/j.1552-4604.1998.tb04398.x

A. Hsu, G. Granneman, and R. Bertz, Erratum to Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents, Clinical Pharmacokinetics, vol.35, issue.6, pp.275-91, 1998.
DOI : 10.1007/BF03259712

V. Soriano, P. Garcya-gasco, and E. , Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial, Journal of Antimicrobial Chemotherapy, vol.61, issue.1, pp.200-205, 2008.
DOI : 10.1093/jac/dkm413

S. Collot-teixeira, D. Lorenzo, F. Waters, and L. , Impact of Different Low-Dose Ritonavir Regimens on Lipids, CD36, and Adipophilin Expression, Clinical Pharmacology & Therapeutics, vol.829, issue.4, pp.375-885, 2009.
DOI : 10.1038/clpt.2008.243

C. Csajka, C. Marzolini, and K. Fattinger, Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency Virus, Antimicrobial Agents and Chemotherapy, vol.48, issue.9, pp.3226-3258
DOI : 10.1128/AAC.48.9.3226-3232.2004

K. Brendel, M. Legrand, and A. Taburet, Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy, Fundamental and Clinical Pharmacology, vol.40, issue.3, pp.373-83, 2005.
DOI : 10.1097/00002030-200305230-00007

B. Kappelhoff, A. Huitema, and S. Sankatsing, Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients, British Journal of Clinical Pharmacology, vol.24, issue.3, pp.276-86, 2005.
DOI : 10.1067/mcp.2002.121424

C. Solas, N. Simon, and M. Drogoul, Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients, British Journal of Clinical Pharmacology, vol.58, issue.3, pp.353-62, 2007.
DOI : 10.1111/j.1742-7843.2006.pto_249.x

C. Verstuyft, F. Marcellin, M. , and L. , Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy, AIDS, vol.19, issue.18, pp.2127-2158, 2005.
DOI : 10.1097/01.aids.0000196122.91633.04

P. Anderson, J. Lamba, and C. Aquilante, Pharmacogenetic Characteristics of Indinavir, Zidovudine, and Lamivudine Therapy in HIV-Infected Adults, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.42, issue.4, pp.441-490, 2006.
DOI : 10.1097/01.qai.0000225013.53568.69

J. Lamba, Y. Lin, and E. Schuetz, Genetic contribution to variable human CYP3A-mediated metabolism, Advanced Drug Delivery Reviews, vol.54, issue.10, pp.1271-94, 2002.
DOI : 10.1016/S0169-409X(02)00066-2

M. Lichterfeld, H. Nischalke, and F. Bergmann, Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy, HIV Medicine, vol.12, issue.1, pp.37-43, 2002.
DOI : 10.1097/00002030-199811000-00024

X. Duval, F. Mentre, and C. Lamotte, Indinavir Plasma Concentration and Adherence Score Are Codeterminant of Early Virologic Response in HIV-Infected Patients of the APROCO Cohort, Therapeutic Drug Monitoring, vol.27, issue.1, pp.63-70, 2005.
DOI : 10.1097/00007691-200502000-00013

J. Dieleman, I. Gyssens, and M. Van-der-ende, Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients, Aids, vol.13, issue.4, pp.473-78, 1999.
DOI : 10.1097/00002030-199903110-00005

X. Duval, F. Mentré, and E. Rey, Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen - ANRS 111 trial, Fundamental & Clinical Pharmacology, vol.42, issue.Suppl. 1, 2008.
DOI : 10.1111/j.1472-8206.2009.00693.x

URL : https://hal.archives-ouvertes.fr/inserm-00416211

D. Hirt, F. Mentré, and A. Tran, Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients, British Journal of Clinical Pharmacology, vol.100, issue.4, pp.548-57, 2008.
DOI : 10.1097/00002030-200001070-00007

URL : https://hal.archives-ouvertes.fr/inserm-00383731

P. Carrieri, V. Cailleton, L. Moing, and V. , The Dynamic of Adherence to Highly Active Antiretroviral Therapy: Results From the French National APROCO Cohort, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.28, issue.3, pp.232-271, 2001.
DOI : 10.1097/00042560-200111010-00005

I. Cascorbi, T. Gerloff, and A. Johne, Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects, Clinical Pharmacology & Therapeutics, vol.69, issue.3, pp.169-74, 2001.
DOI : 10.1067/mcp.2001.114164

H. Dally, L. Edler, and B. Jager, The CYP3A4*1B allele increases risk for small cell lung cancer, Pharmacogenetics, vol.13, issue.10, pp.607-625, 2003.
DOI : 10.1097/00008571-200310000-00004

J. Crow, Hardy, Weinberg and language impediments, Genetics, vol.152, pp.821-846, 1999.

J. Pritchard, M. Stephens, and P. Donnelly, Inference of population structure using multilocus genotype data, Genetics, vol.155, pp.945-59, 2000.

E. Kuhn and M. Lavielle, Maximum likelihood estimation in nonlinear mixed effects models, Computational Statistics & Data Analysis, vol.49, issue.4, pp.1020-1058, 2005.
DOI : 10.1016/j.csda.2004.07.002

M. Lavielle, MONOLIX (MOdèles NOn LInéairesLInéaires`LInéairesà effets miXtes). MONOLIX group, 2008.

M. Lavielle and F. Mentré, Estimation of Population Pharmacokinetic Parameters of Saquinavir in HIV Patients with the MONOLIX Software, Journal of Pharmacokinetics and Pharmacodynamics, vol.32, issue.2, pp.229-278, 2007.
DOI : 10.1007/s10928-006-9043-z

URL : https://hal.archives-ouvertes.fr/inserm-00156907

A. Gelman, J. Carlin, and H. Stern, Bayesian data analysis, 1995.

J. Bertrand, E. Comets, and F. Mentré, Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters, Journal of Biopharmaceutical Statistics, vol.5, issue.6, pp.1084-102, 2008.
DOI : 10.1111/j.1525-1438.2006.00593.x

URL : https://hal.archives-ouvertes.fr/inserm-00339183

C. Goujard, M. Legrand, and X. Panhard, High Variability of Indinavir and Nelfinavir Pharmacokinetics in HIV-Infected Patients with a Sustained Virological Response on Highly Active Antiretroviral Therapy, Clinical Pharmacokinetics, vol.30, issue.12, pp.1267-78, 2005.
DOI : 10.2165/00003088-200544120-00005

U. Fuhr, A. Jetter, and J. Kirchheiner, Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the ???Cocktail??? Approach, Clinical Pharmacology & Therapeutics, vol.75, issue.2, pp.270-83, 2007.
DOI : 10.1038/sj.clpt.6100050

T. Ikezoe, Y. Hisatake, and T. Takeuchi, HIV-1 Protease Inhibitor, Ritonavir: A Potent Inhibitor of CYP3A4, Enhanced the Anticancer Effects of Docetaxel in Androgen-Independent Prostate Cancer Cells In vitro and In vivo, Cancer Research, vol.64, issue.20, pp.7426-7457, 2004.
DOI : 10.1158/0008-5472.CAN-03-2677

S. Zhou, Y. Chan, S. , C. Goh, and B. , Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs, Clinical Pharmacokinetics, vol.20, issue.3, pp.279-283, 2005.
DOI : 10.2165/00003088-200544030-00005

M. Rittweger and K. Arastéh, Clinical Pharmacokinetics of Darunavir, Clinical Pharmacokinetics, vol.10, issue.3, pp.739-56, 2007.
DOI : 10.2165/00003088-200746090-00002

A. Spurdle, B. Goodwin, and E. Hodgson, The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer, Pharmacogenetics, vol.12, issue.5, pp.355-66, 2002.
DOI : 10.1097/00008571-200207000-00003

P. He, M. Court, and D. Greenblatt, Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo, Clinical Pharmacology & Therapeutics, vol.77, issue.5, pp.373-87, 2005.
DOI : 10.1016/j.clpt.2004.11.112

D. Hesselink, R. Van-schaik, and I. Van-der-heiden, Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus, Clinical Pharmacology & Therapeutics, vol.74, issue.3, pp.245-54, 2003.
DOI : 10.1016/S0009-9236(03)00168-1

A. Tran, V. Jullien, and J. Alexandre, Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms, Clinical Pharmacology & Therapeutics, vol.79, issue.6, pp.570-80, 2006.
DOI : 10.1016/j.clpt.2006.02.003

B. Amirimani, B. Ning, and A. Deitz, Increased transcriptional activity of theCYP3A4*1B promoter variant, Environmental and Molecular Mutagenesis, vol.259, issue.4, pp.299-305, 2003.
DOI : 10.1002/em.10199

K. Yeh, J. Stone, and A. Carides, Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: Study design and model???independent data analysis, Journal of Pharmaceutical Sciences, vol.88, issue.5, pp.568-73, 1999.
DOI : 10.1021/js9802392

J. Lu, T. Blaschke, and C. Flexner, Model-based Analysis of the Pharmacokinetic Interactions Between Ritonavir, Nelfinavir, and Saquinavir after Simultaneous and Staggered Oral Administration, Drug Metabolism and Disposition, vol.30, issue.12, pp.1455-61
DOI : 10.1124/dmd.30.12.1455

B. Kappelhoff, A. Huitema, and K. Crommentuyn, Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients, British Journal of Clinical Pharmacology, vol.9, issue.2, pp.174-82, 2005.
DOI : 10.1067/mcp.2002.123553

A. Schön, M. Del-mar-ingaramo, and E. Freire, The binding of HIV-1 protease inhibitors to human serum proteins, Biophysical Chemistry, vol.105, issue.2-3, pp.221-251, 2003.
DOI : 10.1016/S0301-4622(03)00071-1

K. Jones, P. Hoggard, and S. Khoo, Effect of ??1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro, British Journal of Clinical Pharmacology, vol.39, issue.1, pp.99-102, 2001.
DOI : 10.1046/j.1365-2125.2001.01324.x

X. Zhang, R. Schooley, and J. Gerber, ???Acid Glycoprotein Concentration on the Antiviral Efficacy of Human Immunodeficiency Virus Protease Inhibitors, The Journal of Infectious Diseases, vol.180, issue.6, pp.1833-1870, 1999.
DOI : 10.1086/315123

A. Samson, M. Lavielle, and F. Mentré, Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model, Computational Statistics & Data Analysis, vol.51, issue.3, pp.1562-74, 2006.
DOI : 10.1016/j.csda.2006.05.007

URL : https://hal.archives-ouvertes.fr/inserm-00182360

C. Fletcher, Pharmacologic Considerations for Therapeutic Success with Antiretroviral Agents, Annals of Pharmacotherapy, vol.338, issue.9, pp.989-95, 1999.
DOI : 10.1345/aph.19075

D. Burger, P. Hugen, and R. Aarnoutse, A Retrospective, Cohort-Based Survey of Patients Using Twice-Daily Indinavir + Ritonavir Combinations: Pharmacokinetics, Safety, and Efficacy, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.26, issue.3, pp.218-242, 2001.
DOI : 10.1097/00126334-200103010-00003

C. Rayner, K. Galbraith, and J. Marriott, A Critical Evaluation of the Therapeutic Range of Indinavir, Annals of Pharmacotherapy, vol.1, issue.7-8, pp.1230-1267, 2002.
DOI : 10.1345/aph.1A016

G. Behrens, A. Dejam, and H. Schmidt, Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors, AIDS, vol.13, issue.10, pp.63-70, 1999.
DOI : 10.1097/00002030-199907090-00001